Skip to main content
SpringerLink
Log in

Long Term Deferiprone Chelation Therapy

  • Chapter
Book cover Iron Chelation Therapy

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 509))

Abstract

A wide variety of compounds have been tested in animals and humans in order to find drugs which are capable of removing iron from patients with refractory anaemias receiving regular blood transfusions. Parenteral preparations which have been evaluated clinically include desferrioxamine (DFO), diethylene triamine penta-acetic acid (DTPA), desferrithiocin and HBED (N,NL bis (2-hydroxy-benzyl ethylenediamine - NNI diacetic acid). Orally active chelators include 2,3 dihydroxybenzoic acid, pyridoxal isonicotinyl hydrazone, 1,2,dimethylpyrid-4-one (L1, deferiprone) and 1,2 diethylpyrid-4-one). The only two compounds in wide clinical use are DFO and deferiprone. DFO discussed in detail elsewhere in this volume remains standard therapy but because of cost, failure of compliance and, less frequently, toxicity or sensitivity, it is not satisfactory for many patients worldwide, especially in poorer countries where thalassaemia major and other transfusion dependent genetic disorders of haemoglobin are most frequent and antenatal diagnosis and prevention is inadequate or non-existent. In India, deferiprone, known as Kelfer (Cipla, Bombay, India) has been licensed since 1990. In the European Community Countries deferiprone, known as Ferriprox, has been licensed for those patients for whom DFO is contra-indicated or who exhibit serious toxicity to DFO therapy. In this review we shall describe the long term results of therapy with deferiprone either alone or in combination with DFO. Other recent reviews of this drug include those of Addis et al1, Basman Balfour et al2Diav-Citrin et al3Hershko & Hoffbrand4Olivieri5.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Addis A, Loebstein R, Koren G, Einarson TR. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1)Eur J Clin Pharmacol1999; 55: 1–6.

    Article  CAS  Google Scholar 

  2. Barman Balfour JA and Foster RH. Deferiprone. A review of its clinical potential in iron overload in ß-thalassaemia major and other transfusion-dependent diseases.Drugs1999; 58: 553–578.

    Article  Google Scholar 

  3. Diav-O, Koren G. Oral iron chelation with deferiprone.Pediatr Clin NAm1997; 44: 235–247.

    Article  Google Scholar 

  4. Hershko C and Hoffbrand AV. Iron Chelation Therapy.Rev in Clin and Exp Hematol2000; 4: 337–361.

    Article  CAS  Google Scholar 

  5. Olivieri NF. Long-term therapy with deferiprone.Acta Haematol1996; 95: 37–48.

    Article  CAS  Google Scholar 

  6. Al-Refaie FN, Hoffbrand AV. Oral iron chelation therapy.Recent Advances in Haematology1993; 7: Eds. M.K. Brenner, A.V. Hoffbrand. Churchill Livingstone, Edinburgh.

    Google Scholar 

  7. Al-Refaie FN, Hoffbrand AV. Oral iron chelating therapy: the LIexperience.Bailliere’s Clinical Haematology1994; 77: 941–963.

    Article  Google Scholar 

  8. Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV. (1987) 1,2-Dimethyl-3- hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.Lancet1989; i, 1294–1295.

    Google Scholar 

  9. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T. Sheppard L. Effective chelation of iron in beta-thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.Br Med J 1987; 295, 1509–1512.

    Article  CAS  Google Scholar 

  10. Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L. Pharmacokinetis studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one.Clin Pharmacol1990; 488, 255–261.

    Google Scholar 

  11. Matsui D, Klein J, Grunau V, McLelland R, Chung D, St-Louis P, Olivieri N, Koren G, Hermann C. Relationship between the pharmacokinetics and iron excretion pharmacodynamies of the new oral iron chelator 1,2-dimethyl3-hydroxy-pyrid-4-one in patients with thalassemia.Clin Pharmacol Ther1991; 50, 294–298.

    Article  CAS  Google Scholar 

  12. AI-Refaie FN, Sheppard LN, Nortey P, Wonke B, Hoftbrand AV. Pharmacokinetics of the oral iron chelator deferiprone (L1).Br J Haematol1995; 89, 403–408.

    Article  Google Scholar 

  13. Agarwal MB, Gupte SS, Viswanathan C, Vasandano D, Ramanathan J, Desai N, Puniyani RR, Chaablani AT. Long-term assessment of efficacy and safety of Li, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.BrJ Haematol1992; 82, 460–466.

    Article  CAS  Google Scholar 

  14. AI-Refaie FN, Wonke B, Hoftbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (Li) in thalassemia major.Blood1992: 80, 593–599.

    Google Scholar 

  15. Al-Refaie FN, Hershko C, Hoffbrand A, Olivieri NF, Tondury P, Wonke B. Results of long-tern deferiprone (Li) therapy: a report by the International Study Group on Oral Iron Chelators.Br J Haematol1995; 91, 224–229.

    Article  CAS  Google Scholar 

  16. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM, Sonderegger T, Wagner HP. LI (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major.Br J Haematol1990; 76, 550–553.

    Article  CAS  Google Scholar 

  17. Tondury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients.BrJHaematol1998; 101, 413–415.

    Article  CAS  Google Scholar 

  18. Hoftbrand AV, AI-Refaie FN, Davis B, Siritanaratkul N, Jackson BFA, Cochrane J, Prescott E, Wonke B. Long term trial of deferiprone in 51 transfusion dependent iron overloaded patients.Blood1998; 91, 295–300.

    Google Scholar 

  19. Kersten MJ, Lange R, Smeets ME, Vreugdentill G, Roozendaal KJ, Lameijer W, Goudsmit R. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.Ann Hematol1996; 247–252.

    Google Scholar 

  20. Longo F, Fischer R, Engelhardt R, et al. Iron balance in thalassemia patients treated with deferiprone (Abstract).Blood1998; 92, Suppl. i, 325a.

    Google Scholar 

  21. Mazza P, Ammuri B, Lazzari G, Masi C, Palazzo G, Spartera MA, Giuia R, Sebastio AM, Suma V, DeMarco S, Semeraro F, Moscoqiuri R. Oral iron chelating therapy. A single centre interim report on deferiprone (LI) in thalassemia.Haematologica1998; 83, 496–501.

    CAS  Google Scholar 

  22. Olivieri NF, Brittenham JM, Matsui D, Berrovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G. Iron-chelation therapy with oral deferiprone in patients with thalassemia major.NEngl J Med1993; 332, 918–922.

    Article  Google Scholar 

  23. Olivieri NF, Brittenham GM, Armstrong SAM, Basran RKm Daneman R, Daneman N, Iwanchko RM, Talbot AL, Koren G. First prospective randomised trial of the iron chelator deferiprone (LI) and deferoxamine.Blood1995; 86, Suppl. 249a

    Google Scholar 

  24. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Bust AD, Fleming KA. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.N Engl J Med1998: 339, 417–423.

    Article  CAS  Google Scholar 

  25. Cohen AR, Galanello R, Piga A, Di Palma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study.Br J Haematol2000; 108, 305–312.

    Article  CAS  Google Scholar 

  26. Taher A, Chamoun FM, Koussa Saad MA, Khoriaty AI, Neeman R, Mourad FH. Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine.Acta Haematol1999; 101, 173–177.

    Article  CAS  Google Scholar 

  27. Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman P, Mourad F. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.Europ J Haemat2001; (in press).

    Google Scholar 

  28. Del Vecchio GC, Crollo E, Schettini F, Schettini, F, Fischer R, De Mania D. Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting.Acta Haematol2000; 104, 99–102.

    Article  Google Scholar 

  29. AI-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum non-transferrin-bound iron in beta-thalassemia major patients treated with desferrioxamine and (L1).Br J Haematol1992; 82, 431–436.

    Article  Google Scholar 

  30. Wolfe L, Olivieri N, Sallan D, Collan S, Roe V, Propper R, Freedman MH, Nathan DG. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.NEngl J Med1985; 312, 1600–1610

    Article  Google Scholar 

  31. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, Hilson AJW. (1990) High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: Reversal by intensified chelation.Acta Haematol1990; 84, 113–117.

    Article  CAS  Google Scholar 

  32. Modell B, Khan M, Darlison M. Survival of beta thalassemia major in the United Kingdom: data from the UK Thalassaemia Register.Lancet2000; 355, 2051–2052.

    Article  CAS  Google Scholar 

  33. Olivieri NF, Nathan DG, MacMillan JH, Wayne AD, Martin M, McGee A, Koren C, Liu PP, Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia.N Engl J Med1994; 331, 574–578.

    Article  CAS  Google Scholar 

  34. Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major.JClin Path1990; 43, 638–640.

    Article  CAS  Google Scholar 

  35. Chapman, RWG, Hussain MAM, Gorman A, Laulicht M, Politis D, Flynn DM, Sherlock S, Hoffbrand AV. Effect of ascorbic acid deficiency on serum ferritin concentrations in patients with beta-thalassaemia major and iron overload.JClin Path1982; 35, 487–491.

    Article  CAS  Google Scholar 

  36. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89, 739–761.

    CAS  Google Scholar 

  37. Anderson L, Holden S, Davis B, Prescott E, Charrier C, Bunce N, Firmin D, Wonke B, Porter J, Walker JM, Pennell D. Cardiovascular T2-star (T2’) magnetic resonance for the early diagnosis of myocardial iron overload.Europ Heart J(in press).

    Google Scholar 

  38. Anderson L, Porter JB, Wonke B, Walker JM, Holden S, Davies BA, Prescott E, Channier C, Firmin DN, Pennel DJ. Relationship of myocardial iron overload to right and left bventricular function in homozygous beta thalassaemia.Blood2000; Supplement Abstract 2597, 605a.

    Google Scholar 

  39. Anderson L, Wonke B, Prescott E, Holden S, Walker M, Panel DJ. Improved cardioprotection with the oral iron chelater L1 over standard therapy with subcutaneous deferoxamine in iron overload cardiomyopathy.JAmer Cardiac College2001; 37(2), Abst55.

    Article  Google Scholar 

  40. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103, 361–364.

    Article  CAS  Google Scholar 

  41. Diav-Citrin O, Atanackovic G, Koren G. An investigation into the variability in the therapeutic response to deferiprone in patients with thalassemia major.Therapeutic Drug Monitoring1999; 21, 74–81.

    Article  CAS  Google Scholar 

  42. Pippard MJ, Weatherall DJ. Oral iron chelation in thalassaemia: an uncertain scene.Br J Haemato12000; 111, 2–5.

    Google Scholar 

  43. Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron, R, McLelland R, Templeton DM. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator in thalassemia intermediaBlood1992; 79, 2741–2748.

    CAS  Google Scholar 

  44. Cragg L, Hebbel RP, Miller W, Solovey A, Selby S, Enright H. The iron chelator L1 potentiates oxidative damage in iron-loaded liver cells.Blood1998; 92.632–638.

    CAS  Google Scholar 

  45. Link G, Konijn AM, Hershko C. Cardio-protective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-laded heart cells.JLab Clin Med1999; 133, 179–188.

    Article  CAS  Google Scholar 

  46. Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ. Long-term trial with the oral iron chelator 1,2-dimethy1–4-hydroxypyrid-4-one (L1). II. Clinical observations.BrJHaematol1990; 76, 301–304.

    Article  CAS  Google Scholar 

  47. Hoffbrand AV, Bartlett A, Veys PA, O’Connor NTJ, Kontoghiorghes GJ. Agranulocytosis and thrombocytopenia in patient a with Blackfan-Diamond anaemia during oral chelator trial.Lancet1989; ii, 57.

    Google Scholar 

  48. Al-Refaie FN, Wonke B, Wickens DG, Aydinok Y, Hoffbrand AV. Zinc concentrations in patients with iron overload receiving oral iron chelator 1,2- dimethyl-hydroxyprid-4-one or desferrioxamine.J Clin Path1994; 46, 657–660.

    Article  Google Scholar 

  49. Mangiagli A, De Sanctis V, Campisi S, Di Silvestro G, Urso L. Treatment with deferiprone (LI) in a thalassaemia patient with bone lesions due to desferrioxamine.J Paed Endocrinology2000; 13, 677–680.

    Article  CAS  Google Scholar 

  50. Cunningham JM, Al-Refaie FN, Hunter AE, Sheppard LN, Hofbfbrand AV. Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro. Europ JHaemat1994; 52, 176–179.

    Article  CAS  Google Scholar 

  51. Al-Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associated myelotixicity. Eur Haemat 1994; 53, 398–421

    Google Scholar 

  52. Carthew P, Smith AG, Hider RC, Dorman B, Edwards RE, Francis JC. Potentiation of iron accukmulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridnone iron chelator CP94.Biometals1994; 7, 267–271.

    Article  CAS  Google Scholar 

  53. Hershko C, Konijn AM, Huerta M, Rosenmann E, Reims C, Link G. Safety and efficacy of iron chelating therapy with DFO and LI in the gerbil model of hemosiderosis.J Lab Clin Med2001; (in press).

    Google Scholar 

  54. Callea F. Iron chelation with oral deferiprone in patients with thalassemia. (Letter) N Engl J Med 1998; 2:339–1711.

    Google Scholar 

  55. Galanello R, De Virgiliis S, Agus A. Sequential liver fibrosis grading during deferiprone treatment in patients with thalassemia major.9th International Conference on Oral Chelation in the Treatment of Thalassaemia and Other DiseasesHamburg, March 14 25–28 1999;

    Google Scholar 

  56. Piga A, Facello S, Caglioti C, Pucci A, Pietribiasi F. No progression of liver fibrosis in thalassemia major during deferiprone or desferrioxamine iron chelation.Blood1998; 92, Suppl. 2, 216.

    Google Scholar 

  57. Stella M, Pinzello G, Maggio A. Iron chelation therapy with oral iron deferiprone in patients with thalassaemia (Letters)N Engl J Med1998; 339, 1712.

    CAS  Google Scholar 

  58. Wanless JR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, De Sanctis V, Schwartz E, Cohen AR. Absence of deferiprone induced hepatic fibrosis@ a milti centre study.Blood2000; 96, Suppl. 1, 2600, Abstracct 606a.

    Google Scholar 

  59. Berdoukas VA, Lindeman R, Eagle C. Liver assessment in a group of transfusion dependent patients treated with deferiprone and compared to a group of patients treated with desferrioxamine. Forty-First Annual Meeting, American Society of Hematology, December 3–7, New Orleans, LA.Blood1999; 94, Suppl. 1, Abstract3283.

    Google Scholar 

  60. Grady RW, Berdoukas VA, Giardina PJ. Iron chelators: combined therapy could be a better approach. Blood 1998; Suppl. 1, Pt. 2:166.

    Google Scholar 

  61. Shalev O, Repka T, Goldfarb A, Grinberg L, Abramov A, Olivieri NF, Rachmilewitz EA, Hebbel RP. Deferiprone (L1) chelated pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo.Blood1995; 86, 2008–2013.

    CAS  Google Scholar 

  62. Shalev O, Hileti, D, Nortey P, Hebbel RP, Hoffbrand AV. Transport of ’4C-deferiprone in normal, thalassaemic and sickle red blood cells.BrJHaematol1999; 105, 1081–1083.

    Article  CAS  Google Scholar 

  63. Breuer W, Emess MJJ, Pootrakul P, Abramov A, Hershko C, Cabantenik Z1. Desferrioxamine-chelatable iron a component of serum iron-transferrin-bound iron, used for assessing chelation therapy.Blood2001; 97, 792–798.

    Article  CAS  Google Scholar 

  64. Balveer K, Pyar K, Wonke B. Combined oral and parenteral iron chelation in beta thalassaemia major.Med J Malaysia2000; 55, 493–497.

    CAS  Google Scholar 

  65. Taher A, Mourad FH, Sheikh-Taha M, Koussa S, mati A, Neeman R, Hoffbrand AV. Comparison of desferrioxamine, deferiprone and a combination therapy in iron overloaded thalassemia patients.11th International Conference on Oral Chelation -Catania2000; p.144.

    Google Scholar 

  66. Arauju A, Kosaryan M, MacDowell A, Wickens D, Puni S, Wonke B, Hoffbrand AV. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload.British J Haemat1996; 93, 835–837.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Royal Free Hospital, Pond Street, Hampstead, NW3 2QG, London

    Victor A Hoffbrand

  2. Consultant Haematologist, Whittington Hospital, London

    Beatrix Wonke

Authors
  1. Victor A Hoffbrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beatrix Wonke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hebrew University School of Medicine, Jerusalem, Israel

    Chaim Hershko

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Kluwer Academic/Plenum Publishers, New York

About this chapter

Cite this chapter

Hoffbrand, V.A., Wonke, B. (2002). Long Term Deferiprone Chelation Therapy. In: Hershko, C. (eds) Iron Chelation Therapy. Advances in Experimental Medicine and Biology, vol 509. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0593-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0593-8_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-46785-1

  • Online ISBN: 978-1-4615-0593-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation